BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11512406)

  • 41. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
    Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
    Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.
    Machtens S; Serth J; Meyer A; Kleinhorst C; Ommer KJ; Herbst U; Kieruij M; Boerner AR
    World J Urol; 2007 Aug; 25(4):341-9. PubMed ID: 17624533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positron emission tomography in urological oncology.
    Hoh CK; Seltzer MA; Franklin J; deKernion JB; Phelps ME; Belldegrun A
    J Urol; 1998 Feb; 159(2):347-56. PubMed ID: 9649238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical application of positron emission tomography (PET)].
    González P; Massardo T; Canessa J; Humeres P; Jofré MJ
    Rev Med Chil; 2002 May; 130(5):569-79. PubMed ID: 12143279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical PET in Oncology.
    Coleman RE
    Clin Positron Imaging; 1998 Dec; 1(1):15-30. PubMed ID: 14516605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of PET imaging in clinical oncology.
    Valk PE; Pounds TR; Tesar RD; Hopkins DM; Haseman MK
    Nucl Med Biol; 1996 Aug; 23(6):737-43. PubMed ID: 8940715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small animal PET in oncology: the road from bench to bedside.
    Ambrosini V; Quarta C; Nanni C; Pettinato C; Franchi R; Grassetto G; Al-Nahhas A; Fanti S; Rubello D
    Cancer Biother Radiopharm; 2009 Apr; 24(2):277-85. PubMed ID: 19409051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genitourinary tract nuclear oncology.
    Yeh SD
    Urol Radiol; 1992; 14(2):107-14. PubMed ID: 1509627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The National Oncologic PET Registry (NOPR): design and analysis plan.
    Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
    J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of positron emission tomography to study tumors in vivo.
    Hamberg LM; Hunter GJ; Fischman AJ
    Mol Med Today; 1996 Dec; 2(12):528-34. PubMed ID: 9015794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practical Applications of Immunohistochemistry in the Diagnosis of Genitourinary Tumors.
    Xiao X; Hu R; Deng FM; Shen SS; Yang XJ; Wu CL
    Arch Pathol Lab Med; 2017 Sep; 141(9):1181-1194. PubMed ID: 28608721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of the principles of texture analysis and its role in imaging of genitourinary neoplasms.
    Thomas R; Qin L; Alessandrino F; Sahu SP; Guerra PJ; Krajewski KM; Shinagare A
    Abdom Radiol (NY); 2019 Jul; 44(7):2501-2510. PubMed ID: 30448920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney).
    Hammerich KH; Ayala GE; Wheeler TM
    Arch Pathol Lab Med; 2008 Mar; 132(3):432-40. PubMed ID: 18318585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel.
    van der Veldt AA; Smit EF; Lammertsma AA
    Front Oncol; 2013; 3():208. PubMed ID: 23986880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of positron emission tomography in urological oncology.
    Bolton DM
    BJU Int; 2010 Dec; 106(11):1594. PubMed ID: 21078038
    [No Abstract]   [Full Text] [Related]  

  • 56. Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).
    Ponto LL; Ponto JA
    Clin Pharmacokinet; 1992 Apr; 22(4):274-83. PubMed ID: 1606787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.
    Siegel C
    J Urol; 2003 Jul; 170(1):321. PubMed ID: 14571863
    [No Abstract]   [Full Text] [Related]  

  • 58. Re: A Review of the Principles of Texture Analysis and its Role in Imaging of Genitourinary Neoplasms.
    Siegel C
    J Urol; 2020 Mar; 203(3):444. PubMed ID: 31793828
    [No Abstract]   [Full Text] [Related]  

  • 59. What is PET? (an overview of principles).
    McQuaid KR
    Gastrointest Endosc; 2002 Jun; 55(7 Suppl):S51-2. PubMed ID: 12024123
    [No Abstract]   [Full Text] [Related]  

  • 60. [Positron emission tomography (PET): application in urogenital system oncologic diseases].
    Lomeña F; Simó M; Setoain X; Pérez G
    Arch Esp Urol; 2001; 54(6):649-60. PubMed ID: 11512406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.